<?xml version='1.0' encoding='utf-8'?>
<document id="31587356"><sentence text="Clinically relevant drug interactions between statins and antidepressants." /><sentence text="Statins, also known as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, and antidepressant drugs are frequently used in combination due to the high and growing incidence of cardiovascular diseases and psychiatric disorders worldwide" /><sentence text=" Several aspects on management, the risk of adverse events (AEs) occurrence and the potential clinically relevant pharmacokinetic (PK) and pharmacodynamic (PD) drug-drug interactions (DDIs) between these two classes have not been well investigated" /><sentence text=" The aim of the present review was to describe the PK and PD interactions, of clinical relevance, between statins and antidepressant drugs and provide a comprehensive overview of their pharmacological features for appropriate multiple drug regimens" /><sentence text="" /><sentence text="Relevant studies were identified through a literature search of PubMed and the Cochrane databases focusing on clinically relevant DDIs between statins and antidepressants" /><sentence text=" Only papers in English were included in the search" /><sentence text="" /><sentence text="Pharmacodynamic (PD) drug-drug interactions (DDIs) are unlikely to occur as statins are highly selective inhibitors of HMG-CoA reductase with no relevant effect on other enzymes or receptor systems" /><sentence text=" Despite the numerous PK studies on individual drugs belonging to statins and antidepressant agents, only a few case reports regarding specific DDIs are present in the literature and no clinical studies have been performed" /><sentence text=" PK data allow to speculate on potential DDIs, comparing the metabolic pathways, intestinal and liver transporters and elimination routes" /><sentence text=" Overall, second-generation antidepressants, in particular citalopram, escitalopram, mirtazapine, reboxetine and venlafaxine, have weak inhibitory effects on various cytochrome (CYP) isozymes and seem to have a more advantageous DDIs profile in vivo"><entity charOffset="59-69" id="DDI-PubMed.31587356.s12.e0" text="citalopram" /><entity charOffset="71-83" id="DDI-PubMed.31587356.s12.e1" text="escitalopram" /><entity charOffset="85-96" id="DDI-PubMed.31587356.s12.e2" text="mirtazapine" /><entity charOffset="98-108" id="DDI-PubMed.31587356.s12.e3" text="reboxetine" /><entity charOffset="113-124" id="DDI-PubMed.31587356.s12.e4" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e0" e2="DDI-PubMed.31587356.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e0" e2="DDI-PubMed.31587356.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e0" e2="DDI-PubMed.31587356.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e0" e2="DDI-PubMed.31587356.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e0" e2="DDI-PubMed.31587356.s12.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e1" e2="DDI-PubMed.31587356.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e1" e2="DDI-PubMed.31587356.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e1" e2="DDI-PubMed.31587356.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e1" e2="DDI-PubMed.31587356.s12.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e2" e2="DDI-PubMed.31587356.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e2" e2="DDI-PubMed.31587356.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e2" e2="DDI-PubMed.31587356.s12.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e3" e2="DDI-PubMed.31587356.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s12.e3" e2="DDI-PubMed.31587356.s12.e4" /></sentence><sentence text=" Conversely, nefazodone, fluoxetine, paroxetine and fluvoxamine influence considerably CYPs activity with potential effects on statins plasma levels, although pravastatin, pitavastatin and rosuvastatin are not susceptible to inhibition by any CYP"><entity charOffset="13-23" id="DDI-PubMed.31587356.s13.e0" text="nefazodone" /><entity charOffset="25-35" id="DDI-PubMed.31587356.s13.e1" text="fluoxetine" /><entity charOffset="37-47" id="DDI-PubMed.31587356.s13.e2" text="paroxetine" /><entity charOffset="52-63" id="DDI-PubMed.31587356.s13.e3" text="fluvoxamine" /><entity charOffset="159-170" id="DDI-PubMed.31587356.s13.e4" text="pravastatin" /><entity charOffset="172-184" id="DDI-PubMed.31587356.s13.e5" text="pitavastatin" /><entity charOffset="189-201" id="DDI-PubMed.31587356.s13.e6" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e0" e2="DDI-PubMed.31587356.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e1" e2="DDI-PubMed.31587356.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e2" e2="DDI-PubMed.31587356.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e2" e2="DDI-PubMed.31587356.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e2" e2="DDI-PubMed.31587356.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e2" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e2" e2="DDI-PubMed.31587356.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e3" e2="DDI-PubMed.31587356.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e3" e2="DDI-PubMed.31587356.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e3" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e3" e2="DDI-PubMed.31587356.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e4" e2="DDI-PubMed.31587356.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e4" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e4" e2="DDI-PubMed.31587356.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e5" e2="DDI-PubMed.31587356.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31587356.s13.e5" e2="DDI-PubMed.31587356.s13.e6" /></sentence><sentence text=" Albeit no studies have been performed on P-glycoprotein (P-gp), interactions of clinical relevance are unlikely" /><sentence text="" /><sentence text="Although DDIs with antidepressants are potentially, but rarely clinically significant, the use of antidepressants with a more favourable drug interaction profile is advisable" /><sentence text=" An evaluation on DDIs between these drugs can be useful for future PK/PD studies on drug-drug interaction to provide clinicians with more data for appropriate multiple drug regimens" /><sentence text="" /></document>